Authors
Latest:
Resection and Reconstruction of a Solitary Sternal Metastasis After Mastectomy for Breast Cancer: A Case Report and Review of the LiteratureIn May 2005, a 25-year-old female presented to her primary care physician complaining of a newly palpable breast mass that had grown to several centimeters over the course of a few months.
Latest:
An Evidence-Based Argument Is Often the Fastest Route to Immunotherapy AuthorizationMany oncology practices are learning lessons about the importance of persistence, persuasion, and creativity in getting I/O drugs to the patients who need them.
Latest:
Immune System Agents May Move Into Earlier Settings in GU CancersOver the past 5 years, medical oncologists have witnessed the revolutionary impact of immunotherapy on patients with advanced urologic malignancies. Over the next 5 years, these therapies likely will similarly transform urologic surgical care.
Latest:
Dr. Gascoyne on Predictive Biomarker Research in LymphomasRandy Gascoyne, MD, research director, Centre for Lymphoid Cancers at the BC Cancer Agency, discusses the growth of predictive biomarker research in follicular lymphoma and other malignancies.
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Dr Mehra on the Implications of the E3311 Trial in HPV+ Oropharynx CancerRanee Mehra, MD, discusses long-term follow-up data from the phase 2 E3311 trial in patients with HPV-associated oropharynx cancer.
Latest:
Dr. Advani Discusses Front-Line BrentuximabRanjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses the movement of brentuximab vedotin combined with CHOP to the front-line.
Latest:
Dr. Concepcion on Transition to Value-Based Model in UrologyRaoul Concepcion, MD, director of the Comprehensive Prostate Center, discusses the impending transition to a value-based model in urology.
Latest:
A Call to EducateRaoul S. Concepcion, MD, calls for increased oncology education and information sharing among the urology community across the globe, as urologists play a critical role in delivering and managing cancer treatment.
Latest:
Dr. Concepcion on Current Testing Patterns in Urology PracticesRaoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses current testing patterns in urology practices.
Latest:
Dr. Bueno on Gene Expression Signatures for Squamous Cell Lung CarcinomaRaphael Bueno, MD, chief, Division of Thoracic Surgery co-director, Brigham and Women’s Lung Center, vice chairman of Surgery for Cancer and Translational Research, professor at Harvard Medical School, discusses gene expression signatures for squamous cell lung carcinoma.
Latest:
Closing Thoughts on Evolving Antibody-Drug Conjugate LandscapeThe expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.
Latest:
Dr. Murthy on De-Escalation Strategies in HER2-Positive Breast CancerRashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses de-escalation strategies for patients with HER2-positive breast cancer.
Latest:
Recognizing the Role of Bias in Patient Decision MakingDoctors are taught to think through medical decisions by listing a series of options, weighing the risks and benefits of each, and ultimately concluding on the superior option. This comparative maximization approach is drilled into us as medical students and residents.
Latest:
Salgia Summarizes the Benefits of Tepotinib in MET Exon 14–Mutated NSCLCDr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.
Latest:
Dr. Vij on the Integration of Selinexor in Relapsed/Refractory Multiple MyelomaRavi Vij, MD, MBA, discusses the integration of selinexor into the relapsed/refractory multiple myeloma armamentarium.
Latest:
Dr. Vij on the Potential of CELMoDs in Relapsed/Refractory Multiple MyelomaRavi Vij, MD, MBA, discusses the potential of cereblon E3 ligase modulators in relapsed/refractory multiple myeloma.
Latest:
Study Adds Pembrolizumab to Paradigm for Certain Head and Neck CancersA group of researchers at Washington University in St. Louis recently opened a clinical trial to evaluate pembrolizumab as treatment intensification therapy for patients with high-risk locoregionally advanced, previously untreated, HPV-negative head and neck squamous cell carcinomas.
Latest:
Dr. Osarogiagbon on the Effects of the COVID-19 Pandemic on Lung Cancer ScreeningRaymond U. Osarogiagbon, MD, FACP, discusses the long-term effects of the COVID-19 pandemic on lung cancer screenings.
